---
title: "Acetyl Octapeptide-3"
canonical_url: https://peptidelibrary.app/library/acetyl-octapeptide-3
description: "Elongated Argireline analog (SNAP-8) used in topical cosmetics. Not an FDA-approved drug; not WADA-prohibited as a cosmetic peptide."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Acetyl Octapeptide-3

Acetyl Octapeptide-3 (also called SNAP-8 or Acetyl Glutamyl Octapeptide-3) is a cosmetic SNARE-targeting peptide. Acetyl octapeptide-3, sold as SNAP-8, is an elongated analog of acetyl hexapeptide-8 carrying two additional residues, designed as a mimetic of the N-terminal region of SNAP-25.

Elongated Argireline analog (SNAP-8) used in topical cosmetics. Not an FDA-approved drug; not WADA-prohibited as a cosmetic peptide.

Also known as: SNAP-8, Acetyl Glutamyl Octapeptide-3.

Categories: Cosmetic, Experimental.

## Classification

- Type: Cosmetic SNARE-targeting peptide
- Mechanism class: SNARE-pathway cosmetic peptide
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Acetyl octapeptide-3, sold as SNAP-8, is an elongated analog of acetyl hexapeptide-8 carrying two additional residues, designed as a mimetic of the N-terminal region of SNAP-25. Like its shorter relative it is proposed to compete for a position in the SNARE complex that mediates neurotransmitter vesicle fusion, destabilising assembly and reducing calcium-dependent transmitter release in model systems, with the cosmetic aim of softening lines produced by repeated muscle contraction. The extension is claimed by suppliers to improve activity relative to the hexapeptide. Independent comparative data is scarce, and as with all peptides of this size penetration through intact stratum corneum is the limiting factor.

Targets: SNAP-25 / SNARE complex.

Origin: Synthetic acetylated octapeptide.

## Properties

- Molecular formula: C41H70N16O16S
- Molecular weight: ≈1075.2 g/mol
- CAS number: 868844-74-0
- Half-life: Topical; systemic PK not established

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 2
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 2024

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Shin JY et al. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024. 2024. Controlled human trial. Population: 24 healthy adults. Better eye-wrinkle improvement, lower water loss and better elasticity and lifting than the placebo patch; no adverse effects [Source](https://pubmed.ncbi.nlm.nih.gov/39082657/)
2. Avcil M et al. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020. 2020. Human study (early or uncontrolled). Population: Healthy adults with aged skin (number not stated in the indexed abstract). Fine lines and wrinkles 25.8% lower, hydration 15.4% higher, dermal density and thickness 14.2% and 12.9% higher; no skin reactions [Source](https://pubmed.ncbi.nlm.nih.gov/31134751/)

## Safety

Side effects: Mild irritation; Redness.

Risks: Cosmetic ingredient, not a drug; Product concentrations vary.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

Acetyl Octapeptide-3 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Permitted
- Availability: OTC / Supplement

## Frequently asked questions

### What is Acetyl Octapeptide-3?

Elongated Argireline analog (SNAP-8) used in topical cosmetics. Not an FDA-approved drug; not WADA-prohibited as a cosmetic peptide.

### How does Acetyl Octapeptide-3 work?

Acetyl octapeptide-3, sold as SNAP-8, is an elongated analog of acetyl hexapeptide-8 carrying two additional residues, designed as a mimetic of the N-terminal region of SNAP-25. Like its shorter relative it is proposed to compete for a position in the SNARE complex that mediates neurotransmitter vesicle fusion, destabilising assembly and reducing calcium-dependent transmitter release in model systems, with the cosmetic aim of softening lines produced by repeated muscle contraction.

### Is Acetyl Octapeptide-3 FDA approved?

No. Acetyl Octapeptide-3 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Acetyl Octapeptide-3?

Reported half-life for Acetyl Octapeptide-3 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Acetyl Octapeptide-3 banned in sport?

Acetyl Octapeptide-3 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Acetyl Octapeptide-3?

Compounds most often compared with Acetyl Octapeptide-3 include Acetyl Hexapeptide-8, Acetyl Tetrapeptide-3, AHK-Cu and Biotinoyl Tripeptide-1. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [INCI / PubChem SNAP-8](https://pubchem.ncbi.nlm.nih.gov/compound/Acetyl%20octapeptide-3)
- [Class-level evidence — D-tyrosine adds an anti-melanogenic effect to cosmetic peptides — Sci Rep, 2020](https://pubmed.ncbi.nlm.nih.gov/31937863/)
- [Class-level evidence — In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation — Cutan Ocul Toxicol, 2015](https://pubmed.ncbi.nlm.nih.gov/24754410/)
